In the context of drug resistance in cancer cells, ABCG2 has the feature of extruding a wide spectrum of chemically unrelated chemotherapeutic drugs, such as mitoxantrone, camptothecins, and tyrosine kinase inhibitors (TKIs). Here, ABCG2 is linked to cancer.